Chugai has announced that ACE910, inhibits blood factor VIII in people aged 12 years or older and results have been designated by US FDA as a breakthrough therapy for the treatment of hemophilia A. ACE910 is a bispecific antibody created by Chugai’s proprietary antibody engineering technologies for the purpose of mimicking the function of blood coagulation factor VIII.

Chugai press release, September 4, 2015